{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:58:05Z","timestamp":1790740685594,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Glucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged as promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral and subcutaneous semaglutide on body composition and metabolic parameters in patients with T2DM and obesity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 24-week quasi-experimental retrospective study including adults with T2DM and obesity (BMI \u2265 30 kg\/m\u00b2) who were treated with either daily-oral or weekly-subcutaneous semaglutide. Body composition was measured using bioelectrical impedance analysis, evaluating fat mass, fat-free mass, total body water, skeletal muscle mass, and whole-body phase angle. Analytical parameters included lipid profile and glycaemic control. Statistical analyses were performed using SPSS v.26.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Participants (n=88) experienced significant weight loss after treatment with semaglutide (9.5% in subcutaneous, 9.4% in oral, P&amp;lt;0.001). Weight reduction primarily resulted from fat mass reduction without substantial lean mass compromise. Visceral fat area decreased, whiles phase-angle remained stable. Improvements in lipid profiles and glycaemic control were observed, with a decrease in both HbA1c and insulin requirements. Multivariate analysis demonstrated comparable impacts of oral and subcutaneous semaglutide on body composition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Semaglutide, administered orally or subcutaneously, demonstrated positive effects on body composition, metabolic and glycaemic control in patients with T2DM and obesity. This real-world study highlights the potential of bioelectrical impedance analysis in assessing antidiabetic drugs\u2019 impact on body composition, providing valuable insights for future research and clinical applications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1386542","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:03:53Z","timestamp":1717477433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus"],"prefix":"10.3389","volume":"15","author":[{"given":"Beatriz","family":"Rodr\u00edguez Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rodr\u00edguez de Vera G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Belmonte Lomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Manuel","family":"Mesa D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Caballero Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3bal","family":"Morales Portillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Mart\u00ednez-Brocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.322","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.236","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21107","article-title":"GLP-1 Receptor Agonists: Nonglycemic clinical effects in weight loss and beyond","volume":"23","author":"Ryan","year":"2015","journal-title":"Obesity"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.100","article-title":"Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with Type 2 diabetes: a systematic review and meta-analysis","volume":"3","author":"Kamalinia","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01149-x","article-title":"Signalling pathways in obesity: Mechanisms and therapeutic interventions","volume":"7","author":"Wen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc12\u20131925","article-title":"Exenatide-Induced reduction in energy intake is associated with an increase in hypothalamic connectivity","volume":"36","author":"Schl\u00f6gl","year":"2013","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in Type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/db09\u20131694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an APOE\u2013\/\u2013 mouse model","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diabetes Vasc Dis Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.0529\u201311.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3233\/jad-2010\u20131314","article-title":"GLP-1 receptor stimulation reduces amyloid-B peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer\u2019s disease","volume":"19","author":"Li","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J Diabetes"},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrneph.2013.272","article-title":"The gut\u2013renal axis: Do incretin-based agents confer renoprotection in diabetes","volume":"10","author":"Muskiet","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes\/Metabolism Res Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018\u201300070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-s002","article-title":"Classification and diagnosis of diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.20960\/nh.2027","article-title":"Nuevo enfoque de la nutrici\u00f3n. Valoraci\u00f3n del estado nutricional del paciente: funci\u00f3n y composici\u00f3n corporal","volume":"35","author":"Almeida","year":"2018","journal-title":"Nutr Hosp"},{"key":"B26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1249\/01.mss.0000477071.37233.5b","article-title":"Validity: A study of the eight tactile point bioelectrical impedance using the DXA in body fat percentage assessment: 865 board# 261 may 27, 3:30 PM-5:00 PM","volume":"47","author":"Rosen","year":"2015","journal-title":"Med Sci Sports Exerc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12384","article-title":"Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body composition in a community-dwelling older population","volume":"15","author":"Kim","year":"2014","journal-title":"Geriatrics Gerontology Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4537623","article-title":"Evaluation of body composition in hemodialysis thai patients: comparison between two models of bioelectrical impedance analyzer and dual-energy X-ray absorptiometry","volume":"2018","author":"Jayanama","year":"2018","journal-title":"J Of Nutr And Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jfmk4020023","article-title":"Comparison of Dual-Energy X-Ray Absorptiometry (DXA) versus a Multi-frequency Bioelectrical Impedance (InBody 770) Device for Body Composition Assessment after a 4-Week Hypoenergetic Diet","volume":"4","author":"Ant\u00f3nio","year":"2019","journal-title":"J Of Funct Morphology And Kinesiology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1519\/jsc.0000000000002708","article-title":"Comparison of multifrequency bioelectrical impedance vs. Dual-energy X-ray absorptiometry for assessing body composition changes after participation in a 10-week resistance training program","volume":"34","author":"Sch\u00f6enfeld","year":"2020","journal-title":"J Of Strength And Conditioning Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1519\/jsc.0000000000000732","article-title":"Comparison of total and segmental body composition using DXA and multifrequency bioimpedance in collegiate female athletes","volume":"29","author":"Esco","year":"2015","journal-title":"J Of Strength And Conditioning Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2016.02.013","article-title":"MR-based assessment of body fat distribution and characteristics","volume":"85","author":"Baum","year":"2016","journal-title":"Eur J Of Radiol"},{"key":"B33","article-title":"Emerging technologies for nutrition research: potential for assessing military performance capability","volume-title":"Bioelectrical Impedance: A History, Research Issues, and Recent Consensus","author":"Carlson-Newberry","year":"1997"},{"key":"B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7400\/NCM.2022.16.1.5107","article-title":"Aplicaciones del \u00e1ngulo de fase de la bioimpedancia en la nutrici\u00f3n cl\u00ednica","author":"Carreira","year":"2022","journal-title":"Nutr Cl\u00edn Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/0884533614568155","article-title":"Bioimpedance at the bedside","volume":"30","author":"Mulasi","year":"2015","journal-title":"Nutr Clin Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3A, randomised trial","volume":"5","author":"\u00c5hr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/nu14122414","article-title":"Once-Weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-Week prospective Real-Life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/db22-1493-PUB","article-title":"1493-PUB: effects of semaglutide on body composition in obese and diabetic patients attended in internal medicine wards","volume":"71","author":"Gomez","year":"2022","journal-title":"Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J Of Endocrine Soc"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202310_34169","article-title":"Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults","volume":"27","author":"Xiang","year":"2023","journal-title":"European review for medical and pharmacological sciences"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009275","article-title":"Hypothesis concerning the u-shaped relation between body mass index and mortality","volume":"146","author":"Allison","year":"1997","journal-title":"Am J Epidemiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20138587(18)30288\u20132","article-title":"Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76 million adults in the UK","volume":"6","author":"Bhaskaran","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/1535370218818161","article-title":"Body Composition and Mortality in the general population: A Review of Epidemiologic studies","volume":"243","author":"Lee","year":"2018","journal-title":"Exp Biol Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.04.003","article-title":"Impact of body composition changes on the risk of all-cause mortality in older adults","volume":"35","author":"Graf","year":"2016","journal-title":"Clin Nutr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.274","article-title":"Combined effects of weight loss and physical activity on all-cause mortality of overweight men and women","volume":"34","author":"\u00d8stergaard","year":"2010","journal-title":"Int J Obes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2406253\/v1","article-title":"Visceral fat area measured by electrical bioimpedance as an aggravating factor of COVID-19: A study on body composition","author":"Carvalho","year":"2023","journal-title":"Res Square"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3042","article-title":"Obesity and diabetes-Not only a simple link between two epidemics","volume":"34","author":"Chobot","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12710","article-title":"Bioimpedance phase angle indicates catabolism in type 2 diabetes","volume":"32","author":"Dittmar","year":"2015","journal-title":"Diabetes Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41430\u2013018-0159\u20131","article-title":"Phase angle and mortality: A systematic review","volume":"73","author":"Garlini","year":"2018","journal-title":"Eur J Clin Nutr"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/0148607106030004309","article-title":"Phase angle from bioelectrical impedance Analysis: population reference values by age, sex, and body mass index","volume":"30","author":"Bosy-Westphal","year":"2006","journal-title":"J Parenter Enteral Nutr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/01.mco.0000165011.69943.39","article-title":"Bioelectrical Impedance Analysis in Clinical Practice: A New perspective on its use beyond body composition equations","volume":"8","author":"Barbosa-Silva","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(01)00555-X","article-title":"Fat-free and fat mass percentiles in 5225 healthy subjects aged 15 to 98 years","volume":"17","author":"Kyle","year":"2001","journal-title":"Nutrition"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11154\u2013023-09803\u20137","article-title":"Future lines of research on phase Angle: Strengths and limitations","volume":"24","author":"Guerrero","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0806470","article-title":"10-Year follow-up of intensive glucose control in Type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20138587(17)30085\u20132","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2174\/1573399810666140707092506","article-title":"Effect of GLP-1 based therapies on diabetic dyslipidemia","volume":"10","author":"Patel","year":"2014","journal-title":"Curr Diabetes Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocrine Pract"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Can Med Assoc J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1386542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:10:02Z","timestamp":1721383802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1386542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":62,"alternative-id":["10.3389\/fendo.2024.1386542"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1386542","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"article-number":"1386542"}}